7 completed. 7 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Phobia, Specific: new trials by email Literature Review of Phobia, Specific trials Research Report on Phobia, Specific
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders. Valproic Acid, Placebo, Fear reactivation - Phobia, Specific | Phase 2 | Completed | Prof. Dominique de Quervain, MD | 100 | 2016-07-01 | 2018-10-02 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| D-cycloserine and Treatment of Feeding Disorders Behavioral Intervention, d-cycloserine (DCS), Placebo - Feeding Disorders, Specific Phobia | Phase 1 / Phase 2 | Completed | Emory University | 16 | 2013-03-01 | 2014-10-23 |
| Enhancing Exposure Therapy for Snake and Spider Phobias Exposure Therapy with Retrieval, Exposure Therapy with Compound Extinction, Exposure Therapy with Retrieval and Compound Extinction - Specific Phobia | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 120 | 2012-08-01 | 2020-12-08 |
| Treatment Study for Rural Latino Youth With Anxiety Therapist-Assisted by Telephone, Self-Help - Anxiety Disorders, Separation Anxiety Disorder | Phase 1 / Phase 2 | Completed | University of California, San Diego | 43 | 2011-11-01 | 2019-08-15 |
| Quetiapine in Specific Phobia Quetiapine XR, Placebo - Specific Phobia | Phase 2 | Completed | University Hospital Muenster | 60 | 2009-04-01 | 2011-03-31 |
| Study of Escitalopram in the Treatment of Specific Phobia Escitalopram - Phobic Disorders | Phase 2 / Phase 3 | Completed | Connor, Kathryn M., M.D. | 12 | 2002-09-01 | 2005-07-21 |
Anxiety Disorders (4) · Anxiety, Separation (2) · Generalized Anxiety Disorder (2) · Phobia, Social (2) · Feeding and Eating Disorders (1) · Mutism (1) · Obsessive-Compulsive Disorder (1) · Phobic Disorders (1)
Mental Disorders (5) · Neurodevelopmental Disorders (2) · Pathological Conditions, Signs and Symptoms (2) · Phobic Disorders (2) · Signs and Symptoms (2) · Communication Disorders (1) · Language Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Signs and Symptoms, Digestive (1) · Speech Disorders (1)
Behavior Therapy (1) · Cycloserine (1) · Escitalopram (1) · Implosive Therapy (1) · Therapeutics (1) · Valproic Acid (1)
Connor, Kathryn M., M.D. (1) · Emory University (1) · Prof. Dominique de Quervain, MD (1) · University Hospital Muenster (1) · University of California, San Diego (1) · University of South Florida (1) · University of Texas at Austin (1)
United States (5) · Germany (1) · Switzerland (1)
Denise A Chavira, PhD (1) · Dominique JF de Quervain, MD (1) · Kathryn M. Connor, M.D. (1) · Michael J Telch, PhD (1) · Peter M Zwanzger, Prof Dr med (1) · William G Sharp, Ph.D. (1)
F31MH100760 (1), R34MH090149 (1)